Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$30.40
$0.07(0.31%)
At close: 4:00 PM EDT
$30.40
$0.07(0.31%)
Day’s Range― - ―
52-Week Range$16.00 - $33.63
Previous CloseN/A
Volume67.76K
Average Volume (3M)143.68K
Market Cap
$49.05M
Enterprise Value$44.77
Total Cash (Recent Filing)$3.08M
Total Debt (Recent Filing)$3.34M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding1,790,188
10 Day Avg. Volume170,191
30 Day Avg. Volume143,675
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRecord quarterly revenue and sharp year-over-year growth indicate expanding demand for Precipio’s cancer diagnostics. Continued top-line momentum can improve operating leverage, support investment in commercialization, and strengthen the company’s position with healthcare customers over the next several quarters.
Improved Cash GenerationThe shift to positive operating and free cash flow materially improves financial flexibility after deeply negative cash generation in earlier years. Internally generated cash can help fund operations and commercialization while reducing reliance on external capital, provided the improvement remains sustainable.
Conservative Balance SheetLow leverage and substantial equity capitalization provide a comparatively resilient financial base for a growing diagnostics business. Manageable debt reduces pressure on cash resources and leaves more flexibility to support product development, customer expansion, and operating needs through the next several quarters.
Bears Say
Profitability Remains UnprovenDespite revenue and cash-flow improvements, Precipio has not yet established consistent GAAP profitability. Continued net and operating losses can constrain retained capital, weaken returns on equity, and make future performance dependent on sustaining growth and converting it into durable operating leverage.
Pipeline Conversion Execution RiskThe expanded commercial pipeline is not yet equivalent to recurring revenue, creating an execution-dependent growth profile. Failure to convert prospects into active accounts could limit product commercialization, delay operating leverage, and leave near-term results below the company’s growth objectives.
Limited Pathology GrowthModest sequential pathology growth suggests the core laboratory business is currently providing limited incremental expansion. Resource allocation toward products may create future opportunity, but slower pathology momentum could temper overall revenue diversification and increase dependence on successful product commercialization.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $16.00 and its highest was $33.63 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $49.05M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Nov 16, 2026 which is in 70 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on Aug 14, 2026. The company reported -$0.122 earnings per share for the quarter.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,790,188 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -$0.122 in its last earnings report. Following the earnings report the stock price went up 1.702%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Precipio Inc
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
PRPO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful operational and financial improvements: record quarterly revenue (> $7M), strong product revenue acceleration (+35% sequential, +21% vs prior record), positive adjusted EBITDA (~$400K) and $700K operating cash generation leading to a >$3M cash balance. These positives are tempered by modest pathology sequential growth, prior distributor complexity that slowed past ramping, quarter-to-quarter timing/seasonality effects, noted execution risk to convert the expanded pipeline, and an unexplained spike in share trading. On balance, the company emphasized organic improvement and execution plans to sustain growth.View all PRPO earnings summariesTechnical Analysis
Ownership Overview
10.88% Insiders
2.27% Mutual Funds
1.91% Other Institutional Investors
81.41% Public Companies and
Individual Investors